Combination therapies
US11890285B2 · kind B2 · utility
2Cited by
5References
43Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 23, 2020 |
| Grant date | Feb 6, 2024 |
| Priority date | — |
| Expiry date | Aug 16, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a an agent that blocks Programmed Death-1 receptor (PD-1) and Programmed Death Ligand-1 (PD-L1) signaling and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, kits comprising the compositions and methods of use therefor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.